Imaging in the age of precision medicine: Summary of the proceedings of the 10th biannual symposium of the international society for strategic studies in radiology

Radiology

Volumn 279, Issue 1, 2016, Pages 226-238

  Herold, Christian J ^a   Lewin, Jonathan S ^b   Wibmer, Andreas G ^a   Thrall, James H ^c   Krestin, Gabriel P ^d   Dixon, Adrian K ^e   Schoenberg, Stefan O ^f   Geckle, Rena J ^b   Muellner, Ada ^g   Hricak, Hedvig ^g  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 13; FLUORODEOXYGLUCOSE F 18; PENITXAFOR GA 68; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ARTICLE; BIOMEDICINE; COMPUTER ASSISTED TOMOGRAPHY; DECISION MAKING; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MEASUREMENT PRECISION; MEDICAL SOCIETY; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIOACTIVITY; RADIODIAGNOSIS; RADIOGRAPHY; RADIOLOGY; REIMBURSEMENT; SYMPOSIUM; TOTAL QUALITY MANAGEMENT; DIAGNOSTIC IMAGING;

DIAGNOSTIC IMAGING; HUMANS; PRECISION MEDICINE;

EID: 84962783541     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2015150709     Document Type: Article

References (76)

1. Medicine TP. Building a knowledge network for biomedical research and a new taxonomy of disease. Washington, DC: The National Academies Press, 2011. http://www. ncbi.nlm.nih.gov/books/NBK91503/pdf/ TOC.pdf. Accessed November 15, 2013.
2. Romero JM, Brouwers HB, Lu J, et al. Prospective validation of the computed tomo-graphic angiography spot sign score for intra-cerebral hemorrhage. Stroke 2013;44(11): 3097-3102.
3. University of Cincinnati. The Spot Sign for Predicting and Treating intracranial hemorrhage Growth Study (STOP-IT): 2010-2013. Cincinnati, Ohio: University of Cincinnati.
4. Cai W, Kassarjian A, Bredella MA, et al. Tumor burden in patients with neurofbroma-tosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology 2009;250(3):665-673.
5. Nelson HD, Fu R, Goddard K, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the U.S. Preventive Services Task Force Recommendation [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Dec. Report No.: 12-05164-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews.
6. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88(9):1337-1342.
7. Jahanshad N, Rajagopalan P, Hua X, et al. Genome-wide scan of healthy human con-nectome discovers SPON1 gene variant infu-encing dementia severity. Proc Natl Acad Sci U S A 2013;110(12):4768-4773.
8. Braskie MN, Jahanshad N, Stein JL, et al. Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults. J Neurosci 2011; 31(18):6764-6770.
9. National Human Genome Research Institute, Division of Genomic Medicine. A Catalog of Published Genome-Wide Association Studies. http://www.genome.gov/gwastudies/. Published 2010. Updated March 23, 2015. Accessed April 2. 2015.
10. Lango Allen H, Estrada K, Lettre G, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 2010;467(7317):832-838.
11. Mummery CJ, Patterson K, Price CJ, Ash-burner J, Frackowiak RS, Hodges JR. A voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory. Ann Neurol 2000;47(1):36-45.
12. Hofman A, van Duijn CM, Franco OH, et al. The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol 2011;26(8): 657-686.
13. National Institutes of Health. The Cancer Genome Atlas: Program Overview. http:// cancergenome.nih.gov/abouttcga/overview. Accessed July 20, 2015.
14. Frederick National Laboratory for Cancer Research. The Cancer Imaging Archive. http://www.cancerimagingarchive.net/. Accessed July 20, 2015.
15. Diehn M, Nardini C, Wang DS, et al. Identif-cation of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A 2008;105(13):5213-5218.
16. Segal E, Sirlin CB, Ooi C, et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotech-nol 2007;25(6):675-680.
17. Gevaert O, Xu J, Hoang CD, et al. Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data-methods and preliminary results. Radiology 2012;264(2):387-396.
18. Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006.
19. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler K W. Cancer genome landscapes. Science 2013;339(6127): 1546-1558.
20. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366(10):883-892.
21. Hricak H. Oncologic imaging: a guiding hand of personalized cancer care. Radiology 2011;259(3):633-640.
22. Karlo CA, Di Paolo PL, Chaim J, et al. Radi-ogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology 2014;270(2):464-471.
23. Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 2009;69(20): 7986-7993.
24. Burgess DJ. Metabolism: Glutamine connections. Nat Rev Cancer 2013;13(5):293.
25. Day SE, Kettunen MI, Gallagher FA, et al. Detecting tumor response to treatment using hy-perpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med 2007;13(11): 1382-1387.
26. Nelson SJ, Kurhanewicz J, Vigneron DB, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-C] pyruvate. Sci Transl Med 2013;5(198): 198ra108.
27. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in domi-nantly inherited Alzheimer's disease. N Engl J Med 2012;367(9):795-804.
28. Eder M, Schäfer M, Bauder-Wüst U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012;23(4):688-697.
29. Courtesy of Wester JH SM. Beer A, Keller U, et al. Unpublished Data. 2013.
30. Daw R, Finkelstein J, Whitesides GM, et al. Insight: Lab on a chip. Nature 2006;442 (7101):367-418.
31. OsiriX Imaging Software. Advanced Open-Source PACS Workstation DICOM Viewer. http://www.osirix-viewer.com/. Published 2013. Accessed April 12, 2015.
32. Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med 2012;366(6):489-491.
33. UNION TCOTE. Council Directive 97/43/ EURATOM. Health protection of individuals against the dangers of ionizing radiation in relation to medical exposure and repealing, Directive 84/466/Euratom1997.
34. Agency for Healthcare Research and Quality. http://www.ahrq.gov/. Accessed April 12, 2015.
35. Wester HJ. Nuclear imaging probes: from bench to bedside. Clin Cancer Res 2007; 13(12):3470-3481.
36. U.S. Food and Drug Administration. PET Drug Applications: Content and Format for NDAs and ANDAs. http://www.fda.gov/ ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm078738.pdf. Published August 2011. Accessed April 12, 2015.
37. DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. Pharma-coeconomics 2002;20(Suppl 3):1-10.
38. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22(2):151-185.
39. Adams CP, Brantner V V. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006;25(2):420-428.
40. European Federation of Pharmaceutical Industries and Associations. The Pharmaceutical Industry in fgures: Edition 2012. http://www.efpia.eu/documents/19/67/ The-Pharmaceutical-Industry-in-fgures-Edi-tion-2012. Published 2012. Accessed 2013.
41. Thrall JH. Quality and safety revolution in health care. Radiology 2004;233(1):3-6.
42. American College of Radiology. Quality & Safety. http://www.acr.org/Quality-Safety. Published 2013. Accessed April 12, 2015.
43. Kruskal JB, Eisenberg R, Sosna J, Yam CS, Kruskal JD, Boiselle PM. Quality initiatives: Quality improvement in radiology: basic principles and tools required to achieve success. Radio Graphics 2011;31(6):1499-1509.
44. Kruskal JB, Anderson S, Yam CS, Sosna J. Strategies for establishing a comprehensive quality and performance improvement program in a radiology department. Radio-Graphics 2009;29(2):315-329.
45. Abujudeh HH, Kaewlai R, Asfaw BA, Thrall JH. Quality initiatives: Key performance indicators for measuring and improving radiology department performance. Radio-Graphics 2010;30(3):571-580.
46. Johnson CD, Krecke KN, Miranda R, Roberts CC, Denham C. Quality initiatives: developing a radiology quality and safety program: a primer. Radio Graphics 2009;29(4): 951-959.
47. Brook OR, O'Connell AM, Thornton E, Eisenberg RL, Mendiratta-Lala M, Kruskal JB. Quality initiatives: anatomy and patho-physiology of errors occurring in clinical radiology practice. Radio Graphics 2010;30(5): 1401-1410.
48. Thornton E, Brook OR, Mendiratta-Lala M, Hallett DT, Kruskal JB. Application of failure mode and effect analysis in a radiology department. Radio Graphics 2011;31(1):281-293.
49. Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K. Response criteria in oncologic imaging: review of traditional and new criteria. Radio Graphics 2013; 33(5):1323.
50. Prescott J W. Quantitative imaging bio-markers: the application of advanced image processing and analysis to clinical and preclinical decision making. J Digit Imaging 2013;26(1):97-108.
51. Radiological Society of North America. Quantitative Imaging Biomarkers Alliance. http://www.rsna.org/QIBA.aspx. Accessed July 20, 2015.
52. Galanaud D, Perlbarg V, Gupta R, et al. Assessment of white matter injury and outcome in severe brain trauma: a prospective multicenter cohort. Anesthesiology 2012;117(6):1300-1310.
53. Sieren JC, Ohno Y, Koyama H, Sugimura K, McLennan G. Recent technological and application developments in computed tomography and magnetic resonance imaging for improved pulmonary nodule detection and lung cancer staging. J Magn Reson Imaging 2010;32(6):1353-1369.
54. Rubin DL. Creating and curating a terminology for radiology: ontology modeling and analysis. J Digit Imaging 2008;21(4):355-362.
55. Opulencia P, Channin DS, Raicu DS, Furst JD. Mapping LIDC, RadLex™, and lung nodule image features. J Digit Imaging 2011;24(2): 256-270.
56. Baerlocher MO. Canada's slow adoption of new technologies adds burden to health care system. CMAJ 2007;176(5):616.
57. Society of Interventional Radiology. Fact Sheet: Nonsurgical interventional radiology procedures offer less risk, less pain and less recovery time compared to open surgery. Available at: http://www.sirweb.org/news/ newsPDF/About%20Interventional%20Radiology.pdf. Accessed September 23, 2015.
58. Mok TS, Wu YL, Thongprasert S, et al. Geftinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361(10):947-957.
59. Arcila ME, Oxnard GR, Nafa K, et al. Rebi-opsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011;17(5):1169-1180.
60. Yu HA, Sima CS, Huang J, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013;8(3):346-351.
61. Dechet CB, Sebo T, Farrow G, Blute ML, En-gen DE, Zincke H. Prospective analysis of in-traoperative frozen needle biopsy of solid renal masses in adults. J Urol 1999;162(4):1282-1284; discussion 1284-1285.
62. Kaplan I, Oldenburg NE, Meskell P, Blake M, Church P, Holupka EJ. Real time MRI-ul-trasound image guided stereotactic prostate biopsy. Magn Reson Imaging 2002;20(3): 295-299.
63. Elias WJ, Huss D, Voss T, et al. A pilot study of focused ultrasound thalamotomy for essential tremor. N Engl J Med 2013;369(7): 640-648.
64. Wang X, Erinjeri JP, Jia X, et al. Pattern of retained contrast on immediate postproce-dure computed tomography (CT) after particle embolization of liver tumors predicts subsequent treatment response. Cardiovasc Intervent Radiol 2013;36(4):1030-1038.
65. Ryan ER, Sofocleous CT, Schöder H, et al. Split-dose technique for FDG PET/CT-guid-ed percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. Radiology 2013;268(1):288-295.
66. Shah PL, Herth FJ. Current status of broncho-scopic lung volume reduction with endobron-chial valves. Thorax 2014;69(3):280-286.
67. Shindoh J, Seyama Y, Matsuda M, et al. Continuous ultrasound navigation for safe and precise anatomic resection of the liver. Hepa-togastroenterology 2013;60(123):590-594.
68. Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 2011;12(11):997-1003.
69. Baumann F, Schmid C, Bernays RL. Intraop-erative magnetic resonance imaging-guided transsphenoidal surgery for giant pituitary adenomas. Neurosurg Rev 2010;33(1):83-90.
70. Simpson DR, Lawson JD, Nath SK, Rose BS, Mundt AJ, Mell LK. A survey of image-guided radiation therapy use in the United States. Cancer 2010;116(16):3953-3960.
71. Ciardiello F, Arnold D, Casali PG, et al. Delivering precision medicine in oncology today and in future: the promise and challenges of personalised cancer medicine- a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol 2014;25(9):1673-1678.
72. European Science Foundation. Personalised Medicine for the European Citizen: towards more precise medicine for the diagnosis, treatment and prevention of disease (iPM). http://www.esf.org/fleadmin/Public-docu-ments/Publications/Personalised-Medicine. pdf. Published December 9, 2012. Accessed April 20, 2015.
73. European Commission. Horizon 2020 Work Programme 2014-2015. Health, demographic change and wellbeing. http:// ec.europa.eu/research/participants/data/ ref/h2020/wp/2014-2015/main/h2020-wp1415-health-en.pdf. Revised DATE. Accessed April 20, 2015.
74. The White House. Offce of the Press Secretary. Fact sheet: President Obama's precision medicine initiative. http://www.white-house.gov/the-press-office/2015/01/30/ fact-sheet-president-obama-s-precision-medicine-initiative. Published January 30, 2015. Accessed March 10, 2015.
75. European Society of Radiology (ESR). Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR). Insights Imaging 2015;6(2):141-155.
76. Sharp PA, Cooney CL, Kastner MA, et al. The third revolution: the convergence of the life sciences, physical sciences and engineering. Massachusetts Institute of Technology. http://dc.mit.edu/sites/dc.mit.edu/fles/MIT White Paper on Convergence.pdf. Published January 2011. Accessed March 3, 2015.